Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : STOCKS READY TO EXPLODE -- Ignore unavailable to you. Want to Upgrade?

To: CIMA who wrote (592)	4/14/1999 12:45:00 PM
From: Spark	Read Replies (2) \| Respond to of 668

NSTG NorStar Forms Subsidiary...Vee Are City.Com, Inc. Business Wire - April 14, 1999 10:45 FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--April 14, 1999--NorStar Group, Inc. (OTC BB:NSTG), announced today that it has formed Vee Are City.Com, Inc., a corporation. Vee Are City.Com, Inc., is a wholly owned subsidiary of NorStar Group, Inc., and will operate as the management, sales and development company for VeeAreCity.com. All technical, management, operational, and sales personnel are being assigned to Vee Are City.Com, Inc. NorStar believes it will be able to post VeeAreCity.com's URL by the end of this week. VeeAreCity.com's announcement page should be ready by April 19, 1999, as scheduled. As previously announced, the completed VeeAreCity.com site will feature: Virtual Reality Chat Rooms...Virtual Reality Game Rooms...Free Virtual Reality Game Download Center...Online Net Telephone...free email...search engines...digital greeting card center...message boards...technical forums...personals...Internet shopping mall...weather... news...financial reports...stock quotes...web pager...web directories...standard chat rooms...Internet telephony chat rooms... other game rooms...Virtual Reality advertising rooms...and thousands of links to the most interesting sites on the World Wide Web. Jay Sanet, Director of Corporate Development stated, "The work has begun on this exciting new cyber-city." CONTACT: NorStar Group Inc., Fort Lauderdale Jay Sanet, Director of Corporate Development 954/772-0240, Fax 954/492-0155 Email: NSTG@bellsouth.net

To: CIMA who wrote (592)	5/10/1999 10:49:00 AM
From: Benoit De Guffroy	Read Replies (1) \| Respond to of 668

EPHI it's ready to moving!!! shorts will be killed !! -------------------------------------------------------------------------------- Related Quotes EPHI 0.710000 -0.140000 delayed 20 mins - disclaimer Monday May 10, 10:14 am Eastern Time Company Press Release Electropharmacology Restructures Along Two Focus Product Areas POMPANO BEACH, Fla.--(BUSINESS WIRE)--May 10, 1999-- Electropharmacology, Inc.'s (Gemini Health Technologies, Inc.) (OTC BB: EPHI - news) management is implementing a plan to continually update shareholders as it implements its new business - developing and commercializing proprietary biotechnology products and services. The company recently restructured itself to develop what its management believes are two major technologies - drug delivery and drug design to address the needs in treating complex diseases such as cancer, tissue degenerative diseases and inflammation. Electropharmacology states that its primary focus is to execute its detailed business plan of acquisitions and manage growth in order to Maximize Future Shareholder Value. By partnering with Elan Group (NYSE: ELN - news; investment transaction & corporate partnering) Electropharmacology will be continually updating its shareholder base with expansion and growth initiatives. The two focus product areas are: - Drug Delivery - an emerging market of over twelve billion dollars, growing at 20% + annually. Electropharmacology plans on taking ''drug delivery'' technologies into clinical testing in 1999, supporting agreements with Pharmaceutical and Biotech companies to generate licensing income in the year 2000. Additional treatments can be developed for chronic degenerative disorders such as arthritis, osteoporosis, and Alzheimer's disease. Biotech and Pharmaceutical companies involved in the drug design field are Merck (NYSE:MRK - news) Monsanto (NYSE:MTC - news), Eli Lilly (NYSE:LLY - news). Other companies involved in drug development and clinical trials are Merck (NYSE:MRK - news), American Home Products (NYSE:AHP - news), Warner Lambert (NYSE:WLA - news), and Genentech (NYSE:GNE - news). - Drug Design - widely expected to revolutionize the entire pharmaceutical industry. The company plans to sell custom designed molecular reagents to two rapidly growing markets: medical genomics research and gene-targeted drug/diagnostic product development companies. Other similar drug design companies are: Millennium (NASDAQ:MLNM - news), and Vertex (NASDAQ:VRTX - news). According to analysts, each of these fields; tissue healing, cancer treatments and drug delivery are generating billions of dollars in revenue and are growing dramatically. When asked to comment, Dr. A. Sen, President, said, ''We are pleased with our strategic alliance with the Elan Group, (http://www.elan.ie) as they are a leader in drug delivery technologies and products. Elan has a proven track record of developing and marketing drugs, in many areas including Parkinson's disease, epilepsy, musculoskeletal conditions, migraine headaches, arthritis, and hypertension. It is an honor to be recognized and associated with such partners.'' Shareholders can receive a complete disclosure of its restructuring in its annual 10K filing. Electropharmacology, Inc. is a Florida based biotechnology services and products provider for both the drug design and drug delivery markets, through its patented products and corporate partners. The foregoing Press Release contains forward looking statements, and any statements contained in this Press Release that are not statements of historical fact may be deemed to be forward looking. These statements by their nature involve substantial risks and uncertainties and actual results may differ. -------------------------------------------------------------------------------- Contact: Electropharmacology, Inc. Dr. A. Sen tel: 352/367-9088 geminihealth.com or Infotivity Technologies, Inc. Greg Lohr tel: 412\384-5535 greglohr@infotivity.com --------------------------------------------------------------------------------